This is a Phase 2 open label, multi-center non-randomized interventional study designed to
evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously
treated metastatic HR-positive, HER2-negative breast cancer.
- This research study involves the study drug Neratinib
- The standard of care drug Fulvestrant